

VU Research Portal

Clinical implications of immunogenicity

Bartelds, G.M.

2011

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Bartelds, G. M. (2011). *Clinical implications of immunogenicity*. [PhD-Thesis – Research external, graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CONTENTS

Chapter 1	General introduction	9
Chapter 2	High levels of human anti-human antibodies (HAHAs) to adalimumab in a patient not responding to adalimumab therapy	21
Chapter 3	Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis	25
Chapter 4	The clinical relevance of immunogenicity in a long-term follow-up cohort of adalimumab treated rheumatoid arthritis patients	39
Chapter 5	Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-TNF naive patients: a cohort study	55
Chapter 6	The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept	67
Chapter 7	Anti-adalimumab antibodies in Rheumatoid Arthritis are associated with Interleukin 10 Gene Polymorphisms	79
Chapter 8	Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study	83
Chapter 9	The effect of immunomodulators on the immunogenicity of TNF blocking therapeutic monoclonal antibodies: a review	97
Chapter 10	Venous and arterial thromboembolic events in adalimumab treated patients with anti-adalimumab antibodies: a case series and cohort study	107
Chapter 11	Summary and general discussion	119
	Nederlandse samenvatting	131
	List of publications	141
	Dankwoord	143
	Curriculum Vitae	147

